KLF16 and urinary bladder cancer: In urinary bladder cancer, STIL contributes to cell proliferation by inhibiting primary cilia formation through its interaction with AURKA [29], while in triple-negative breast cancer, it promotes malignancy by activating the Fanconi anemia pathway through KLF16 interactions [31].